CA3235310A1 - Neutralizing monoclonal antibodies against sarbecoviruses - Google Patents
Neutralizing monoclonal antibodies against sarbecoviruses Download PDFInfo
- Publication number
- CA3235310A1 CA3235310A1 CA3235310A CA3235310A CA3235310A1 CA 3235310 A1 CA3235310 A1 CA 3235310A1 CA 3235310 A CA3235310 A CA 3235310A CA 3235310 A CA3235310 A CA 3235310A CA 3235310 A1 CA3235310 A1 CA 3235310A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205626.1 | 2021-10-29 | ||
| EP21205626.1A EP4174083A1 (en) | 2021-10-29 | 2021-10-29 | Neutralizing monoclonal antibodies against sarbecoviruses |
| PCT/IB2022/056706 WO2023073441A1 (en) | 2021-10-29 | 2022-07-20 | Neutralizing monoclonal antibodies against sarbecoviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235310A1 true CA3235310A1 (en) | 2023-05-04 |
Family
ID=78414544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235310A Pending CA3235310A1 (en) | 2021-10-29 | 2022-07-20 | Neutralizing monoclonal antibodies against sarbecoviruses |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP4174083A1 (enExample) |
| JP (1) | JP2024540147A (enExample) |
| AU (1) | AU2022374853A1 (enExample) |
| CA (1) | CA3235310A1 (enExample) |
| IL (1) | IL312392A (enExample) |
| WO (1) | WO2023073441A1 (enExample) |
-
2021
- 2021-10-29 EP EP21205626.1A patent/EP4174083A1/en active Pending
-
2022
- 2022-07-20 IL IL312392A patent/IL312392A/en unknown
- 2022-07-20 JP JP2024525544A patent/JP2024540147A/ja active Pending
- 2022-07-20 EP EP22743926.2A patent/EP4423124A1/en active Pending
- 2022-07-20 AU AU2022374853A patent/AU2022374853A1/en active Pending
- 2022-07-20 CA CA3235310A patent/CA3235310A1/en active Pending
- 2022-07-20 WO PCT/IB2022/056706 patent/WO2023073441A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4423124A1 (en) | 2024-09-04 |
| JP2024540147A (ja) | 2024-10-31 |
| EP4174083A1 (en) | 2023-05-03 |
| IL312392A (en) | 2024-06-01 |
| WO2023073441A1 (en) | 2023-05-04 |
| AU2022374853A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013229488B2 (en) | Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof | |
| CA2703667A1 (en) | Anti-rsv g protein antibodies | |
| US20240182549A1 (en) | Peptides and antibody fusions that bind to sars-cov-2 and methods of using same | |
| JP2013505236A (ja) | Ｈｉｖ−１抗体 | |
| WO2025246679A1 (zh) | 一种广谱中和冠状病毒的抗体及其应用 | |
| CN103224559B (zh) | 人源hiv广谱中和抗体a16及其相关生物材料与应用 | |
| CA3235310A1 (en) | Neutralizing monoclonal antibodies against sarbecoviruses | |
| WO2021105669A1 (en) | Antibodies | |
| Pavan et al. | Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants | |
| WO2024209076A1 (en) | Combined antibodies against sarbecoviruses and uses thereof | |
| CN116675766A (zh) | 人源化高中和活性抗新型冠状病毒单克隆抗体及应用 | |
| Li et al. | N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies | |
| CN107383190A (zh) | 人源抗HIVgp41特异性抗体及其应用 | |
| TW202346329A (zh) | 冠狀病毒之特異性抗體及其用途 | |
| CN121335920A (zh) | 靶向HIV Env上的CD4结合位点的广谱中和抗体 | |
| CA2509387A1 (en) | Peptide oligomers for use as hiv vaccines | |
| IL278955A (en) | Antibodies against sars cov-2 | |
| CN102212133B (zh) | 人源HIV抗体的Fab片段及其编码基因与应用 | |
| CN119371521A (zh) | 一种广谱抗新型冠状病毒SARS-CoV-2的纳米抗体及其应用 | |
| HK1200176B (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
| NZ729856B2 (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S) Effective date: 20240923 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250711 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250711 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20251204 |